storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Hard tissue, referring to "normal" calcified tissue, is tissue which is mineralized and has a firm intercellular matrix. The hard tissues of humans are bone, tooth enamel, dentin, and cementum. The term is in contrast to soft tissue.
21 April – Mark Menzies quits the Conservative Party and says he will stand down from Parliament at the next election. Robin Swann, who is the perspective Ulster Unionist candidate for South Antrim, announces he will step down from his post as Northern Ireland's Health Minister once the general election campaign begins. 22 April – Parliament passes the Safety of Rwanda Bill, with plans to deport the first asylum seekers to Kigali in July. Two men, including a parliamentary researcher, are charged with spying for China after providing information that could be "useful to an enemy". Conservative councillor Richard Solesbury-Timms, who represents Middleton Cheney on West Northamptonshire Council, leaves the party to sit as an independent citing the party's dealing with allegations against the council leader. 23 April – Patrick Harvie says he will resign as co-leader of the Scottish Greens if the party votes to end its coalition agreement with the SNP. Alliance Party MLA Patrick Brown resigns his South Down seat in the Northern Ireland Assembly, citing personal reasons for doing so. 24 April – Rishi Sunak vows to increase UK defence spending to 2.5% of GDP by 2030. Labour unveils its plans for improvements to train services, which include automatic refunds for delays, a "best price" guarantee and improved internet coverage. Jeffrey Donaldson appears at Newry Magistrates' Court to face charges of historic child abuse. Johnny Timpson, the UK's inaugural disability ambassador, resigns over the UK government's policy of clawing back benefit overpayment.
== Victims == March 23/24, 2017: Archie Edgell, 84, a United States Army veteran of the Korean War July 19/20, 2017: Robert Edge Sr., 82, a United States Navy veteran of the Korean War January 28/29, 2018: Robert Kozul, 89, a United States Army veteran of the Korean War March 25/26, 2018: George Shaw Sr., 81, a United States Air Force veteran April 3 or 4, 2018: William Holloway, 96, a United States Army veteran of World War II April 8 or 9, 2018: Felix McDermott, 82, a United States Army veteran of the Vietnam War June 3/4 2018: Raymond Golden, 88, a United States Army and United States Air Force veteran of the Korean War and the Vietnam War June 17 or 18, 2018: Russell R. Posey Sr., 92, a United States Navy veteran of World War II. Posey later died at a nursing home on July 3, 2018. The medical examiner could not conclusively confirm that the insulin with which Mays injected him had been the direct cause of death. Mays was convicted on one count of assault with intent to commit murder in connection with the assault on Posey.
In Ethiopia, the Civil Aviation Accident Prevention and Investigation Bureau of the Ethiopian Civil Aviation Authority (ECAA), which is an agency of the Ministry of Transport and Communications, conducts aircraft accident investigations in Ethiopia or involving Ethiopian aircraft. In France, the agency responsible for investigation of civilian air crashes is the Bureau d'Enquêtes et d'Analyses pour la Sécurité de l'Aviation Civile (BEA). Its purpose is to establish the circumstances and causes of the accident and to make recommendations for their future avoidance. In Germany, the agency for investigating air crashes is the Federal Bureau of Aircraft Accidents Investigation (BFU). It is an agency of the Federal Ministry of Transport and Digital Infrastructure. The focus of the BFU is to improve safety by determining the causes of accidents and serious incidents and making safety recommendations to prevent recurrence.
Sources: en.wikipedia.org
Plutonium-239 (239Pu or Pu-239) is an isotope of plutonium. Plutonium-239 is the primary fissile isotope used for the production of nuclear weapons, although uranium-235 is also used for that purpose. Plutonium-239 is also one of the three isotopes that have been demonstrated to be usable as fuel in thermal spectrum nuclear reactors, along with uranium-235 and uranium-233. Plutonium-239 has a half-life of 24,110 years.
==== Australia ==== Prescription medicine (Schedule 4) for therapeutic use containing two percent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A Schedule 4 drug under the SUSMP is a Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by state or territory legislation to prescribe and should be available from a pharmacist on prescription. In June 2020, the Australian Therapeutic Goods Administration (TGA) published a consultation on a proposal to pave the way to make "low dose" CBD available to consumer/patients via pharmacists only through moving products from Schedule 4 to 3. Any products sold would need to have their safety, quality and efficacy pre-assessed by the TGA and be formally approved for sale (details to be outlined by TGA). They would be made available to over 18s only, with the maximum daily dose of 60 mg/day, up to 2% THC finished product allowed, 30-day maximum supply, plant-derived or synthetic. This proposal is based on an initial literature review on the safety of low dose CBD published by the TGA in April 2020. Epidyolex was approved for the adjunctive therapy of seizures associated with Lennox–Gastaut syndrome or with Dravet syndrome in September 2020.
=== Russian aid to Cuba === On 30 March, a Russian oil tanker, the Anatoly Kolodkin, carrying 100,000 tonnes of crude oil, or 730,000 barrels, arrived in Havana. The Russian shipment could be converted into 250,000 barrels of diesel which could cover Cuban energy demands for 12 and a half days. The Guardian argued that the docking of the Russian tanker signals greater American flexibility in the ability of Cuba to purchase oil from abroad. On 27 May, the Universal, a Russian fuel tanker, failed to reach Cuba, turning around off the coast of Brazil. The vessel itself is subject to U.S. sanctions and some speculate that the ship was interceded by American naval authorities.
a vaginal bulge the feeling that something is falling out of the vagina the sensation of pelvic heaviness or fullness difficulty starting a urine stream a feeling of incomplete urination frequent or urgent urination fecal incontinence frequent urinary tract infections back and pelvic pain fatigue painful sexual intercourse bleeding A bladder that has dropped from its normal position and into the vagina can cause some forms of incontinence and incomplete emptying of the bladder.
=== Order of magnitude estimates === The following table illustrates the range of viscosity values observed in common substances. Unless otherwise noted, a temperature of 25 °C and a pressure of 1 atmosphere are assumed. The values listed are representative estimates only, as they do not account for measurement uncertainties, variability in material definitions, or non-Newtonian behavior.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.